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Do we need endothelin antagonists? 
Thomas F Luscher 
he arsenal of therapeutic agents available in clinical 
practice has expanded dramatically in the last T I00 years. In cardiovascular pharmacotherapy, 
digoxin and nitrates were the first agents available.' * In the 
Vascular effects of endothelin and its receptors 
K i' 
last decades, diuretics, reserpine, p  blocker^,^ calcium 
antagonists? and most recently angiotensin converting 
en7yme inhibitors' have been added to the armamentorium 
of cardiovascular care. The advent of a new class of drugs 
is a rare event in most areas of medicine and usually occurs 
once in a decade or even less. 
Drugs may either be introduced solely on the basis of 
circumstantial evidence that they work or they may be 
derived from the discovery of a new regulatory system. An 
example of the former is the introduction of nitrates by 
Thomas Lauder Brunton in the last century.* Indeed, 
Dr Brunton had no idea of the mechanism of action of the 
drugs he was using, nor did he understand the disease he was 
treating. Yet his therapeutic approach is still common clinical 
practice.6 On the other hand, p blockers and particularly 
angiotensin converting enzyme inhibitors have been derived 
from the discovery of new regulatory mechanisms in the 
cardiovascular system. Similarly, endothelin antagonists 
have now become available shortly after the discovery of the 
potent 21 amino acid peptide endothelin by Yanagisawa and 
coworkers in 198g7 and the cloning of its receptors in 
1990.8-10 
Endothelins are a family of peptides with potent biological 
effeck7-16 Endothelin-1, -2, and -3 are formed from pre- 
cursor molecules (big endothelin) via the activity of a 
putative endothelin converting enzyme (ECE; figure). 
Endothelin-1 appears to be the primary product of endo- 
thelial cells. In vitro and in vivo, endothelin is a very potent 
vasoconstrictor' "-I7 but under certain conditions, however, 
it also causes transient vasodilatation? l2 '' In addition, 
endothelin potentiates the effects of other vasoconstrictor 
 hormone^,'^-*^ stimulates migration and proliferation of 
vascular smooth m ~ s c l e , ~ ~ - * ~  and exerts renal and endocrine 
effects.25 Two endothelin receptors have been cloned, the 
ETA receptor which preferentially binds endothelin- 1 and 
the ETB receptor which has an equal affinity for all isoforms 
of endothelins? In addition, a putative ETc receptor with 
preferential binding of endothelin-3 has also been pro- 
although its existence remains contr~versial .~~ The 
vasoconstrictor effects of endothelin in vascular smooth 
muscle are mediated by ETA receptors and in certain blood 
vessels also by an ETB re~ep to r .*~-~~  The vasodilator actions 
of endothelins, which are particularly seen with intraluminal 
application of a bolus of the peptide and in small and 
t Endothelium 
NO PGI? 
Vascular effects of endothelin (ET) and its receptors: ETA and ET, 
receptors are expressed on vascular smooth muscle to mediate 
contraction and proliferation, while endothelial cells only express 
ET, receptors linked to the formation of nitric oxide (NO) and 
prostacyclin (PGI,). These mediators are responsible for the vaso- 
dilatation occurring under these conditions via increases in cyclic 
GMP and cyclic AMR respectively. ECE = endothelin converting 
enzyme; circles = receptors. 
resistance ar ter ie~,~ l 8  is mediated by an ETB receptor on 
endothelial cells linked to the formation of vasodilator 
substances such as nitric oxide and prostacyclin (figure). 
Although endothelin has impressive biological effects 
within the cardiovascular system on vascular tone and 
growth as well as on renal function, its physiological role 
still remains controversial. This is mainly due to the lack of 
specific inhibitors interfering with the effects of endo- 
genously produced endothelin. Indeed the fact that circu- 
lating levels of endothelins are very low under normal 
conditions suggests that the peptide acts as a local vascular 
regulatory system rather than as a circulating hormone. This 
also makes it unlikely that the vast number of pharmaco- 
logical studies published""" " with infusion or application of 
high concentrations of endothelin do indeed have physio- 
logical relevance. Although the question raised in this review 
appears to be aiming at therapeutic implications of the newly 
developed endothelin antagonists, an equally important 
aspect of such molecules may be the fact that they will serve 
as specific tools to study the physiological importance of 
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endogenously formed endothelin in the cardiovascular 
system. 
An increasing number of molecules interfering with one or 
both endothelin receptors have become available for experi- 
mental studies (table l).3'43 Most of the first generation 
molecules are specific antagonists of the ETA At 
first sight, these molecules would appear ideal drugs as they 
primarily interfere with the ETA receptor on vascular smooth 
muscle which mediates vasoconstriction, while leaving the 
ET, receptor on endothelial cells untouched (figure). It soon 
became apparent, however, that in  several vascular beds, ETB 
receptors on vascular smooth muscle also contribute import- 
antly to vasoconstriction.'X-'" Indeed, particularly in the renal 
circulation but also in certain human arteries and in veins, 
ETB receptors mediate vasoconstrictor effects of the peptide. 
This led to a change in concept and strongly suggested that 
molecules interfering with both ET, and ET, receptors might 
be much more appropriate for further development as 
therapeutic agents. Several of these compounds are now 
tested at the experimental level (table I).KJh A major draw- 
back of the molecules at this point is the fact that they cannot 
be used for human in vivo studies yet and are usually only 
poorly available via the oral route. Furthermore, their safety 
is uncertain. 
Do we need endothelin antagonists in clinical medicine 
and if so. t'or which diseases? There are a number of disease 
states associated with increased circulating levels of endo- 
thelin itable " Indeed, almost every vascular disease 
such as atherosclerosis,j' Takayashu's disease, Raynaud's 
disease,4x and others is associated with increased circulating 
levels of the peptide. Similarly. in migraine," cerebral 
vasospasm after subarachnoid haem~rrhage,~' and coronary 
spasm,5' '' increased local or circulating levels of the peptide 
have been reported. There is also good experimental and 
clinical evidence that endothelin production is stimulated 
during myocardial ischaemia and infarctiod' " and that the 
Table IZ Disease m i e s  with increased circidating endorhclin 
levels. 
I Vascular d I sease Atherosclerosis 
Takayashu's disease 
Raynaud's disease 
Coronary spasm 
Cardiac shock 
Heart failure 
111 Hypertemion Arterial hypertension (?) 
Pulmonary hypertension 
IV Other diseases hligraine 
Subarachnoid haernorrhage 
Renal failure (acute and chronic) 
Hepatorenal syndrome 
I t  Heart disease Myocardial infarction 
increased production of the peptide may contribute to infarct 
size and extension.55 Endothelin may be stimulated under 
these conditions by thrombin7 56 which is abundantly present 
in clots, as well as by hy~ox ia . ' ~  Hypoxia and ischaemia can 
also externalise endothelin receptors.'' 
Pulmonary hypertension is another clinical syndrome in 
which endothelin has been im~licated, '~ while in systemic 
arterial hypertension, the published results are very contro- 
versial."' I 1  32 Indeed, while some investigators found normal 
values in patients with essential hypertension, others 
reported increased levels, most commonly in small sample 
studies."' '@'' The controversial results in arterial hyper- 
tension may be related to the presence or absence of vascular 
disease and/or renal failure or possibly also reflect a hetero- 
geneity of hypertensive patients with regard to the activation 
of endothelin production. Increased vascular . endothelin 
levels could certainly mediate an increase in peripheral 
vascular resistance which is the hallmark of arterial hyper- 
tension. True endothelin dependent hypertension has been 
described in patients with endothelin producing tumours 
(haemangiopericytomas) in which the contribution of 
endothelin to blood pressure regulation is obvious?' In 
addition to these cardiovascular disease states, endothelin 
has been implicated in other clinical conditions such 
as asthma,69 7" while its role in Crohn's disease is 
controver~ial.~' 72 
However, we should not derive our indications only from 
the fact that circulating endothelin levels are increased in a 
given disease state. Indeed, as endothelin primarily acts as 
a local vascular regulator and two thirds of the endothelin 
produced by endothelial cells is released abluminally rather 
than l~minal ly ,~ '  endothelin may contribute importantly to a 
cardiovascular disease process even in the presence of 
normal circulating levels of the peptide. In line with this 
concept, endothelin  antagonist^,'^ in particular those inter- 
fering with both the ETA and ETB receptors but also 
endothelin converting enzyme  inhibitor^,^' do lower blood 
pressure in spontaneous and DOCA salt hypertension in the 
rat,74 although circulating levels of endothelin are normal or 
even low in these models of hypertension.6" Similarly, local 
spastic events in certain parts of the cardiovascular system 
such as the coronary" '* and cerebral circulation5" may be 
mediated by an increased endothelin production in the 
diseased vascular segment, but the amount of endothelin 
released luminally may not be sufficient to increase 
circulating endothelin levels in these patients. 
What would be the most appropriate indications for 
endothelin antagonists in clinical medicine? Obviously this 
question cannot be addressed appropriately as the data 
supporting one statement or another are still lacking. How- 
ever, experimental studies strongly suggest that endothelin 
antagonists are able to lower blood pressure. In addition they 
may have the capacity to reduce the occurrence of cardio- 
vascular complications of the hypertensive process such as 
stroke.74 
If endothelin antagonists do lower blood pressure, do we 
need another antihypertensive agent, as so many are already 
available? It is obvious that the currently available 
drugs such as diuretics, f3 blockers, ACE inhibitors, and 
calcium antagonists are very potent and well tolerated anti- 
hypertensive drugs which are more or less equally effective 
in lowering blood pressure. Combination therapy with these 
antihypertensive drugs allows control of the blood pressure 
in the vast majority of hypertensive patients. Hence from a 
haemodynamic point of view another antihypertensive agent 
is not what the cardiovascular community is necessarily 
waiting for. However, antihypertensive therapy is far from 
perfect with regard to the prevention of hypertensive 
complications (for example, stroke, myocardial infarction, 
and renal failure) and this indeed is the true aim of anti- 
hypertensive therapy. Currently, antihypertensive drugs are 
quite effective in reducing haemorrhagic and ischaemic 
stroke as well as left ventricular failure in patients with 
hypertension. However, even treated hypertensive patients 
do not reach the risk profile of normotensive patients and the 
effect of antihypertensive drugs on coronary artery disease 
and renal dysfunction (at least in certain patients) is even less 
satisfying. Hence there is a place for a new antihypertensive 
agent capable not only of lowering pressure but also of 
effectively interfering with vascular dysfunction and in turn 
preventing vascular morbidity and death. Endothelin may be 
an important mediator in this context as the peptide is a 
locally released vasoconstrictor which also has migratory 
and proliferative proper tie^.*^-'^ The fact that the peptide is 
produced in increased amounts in any form of human 
vascular disease47 48 suggests that it is either a marker or an 
important mediator of vascular damage. 
Furthermore, experiments with cyclosporin induced renal 
dysfunction indicate that endothelin antagonists may have a 
role in preventing the untoward effects of cyclosporin within 
the kidney and the v a s ~ u l a t u r e . ~ ~ ~ ~  Indeed, infusion of 
endothelin antagonists can prevent the decrease in renal 
blood flow induced by cyclosporin A.79 
In addition, endothelin antagonists may be very promising 
in preventing and possibly also reversing acute renal 
failure." In both acute and chronic renal failure, plasma 
endothelin levels are i n ~ r e a s e d . ~ ~  8' 82 Most interestingly, 
endothelin antagonists have been shown to prevent or 
reduce cerebral vasospasm occurring after experimental sub- 
arachnoid haern~rrhage. '~-~~ In addition, at this stage we 
certainly should keep our eyes open and test this new class 
of drugs in pulmonary hypertension, migraine, coronary 
spasm, and evolving myocardial infarction. Indeed, in myo- 
cardial infarction the duration of the increase of circulating 
endothelin has been related to the outcome of the patientss4 
and at the experimental levels, endothelin antibodies have 
been shown to reduce infarct size.55 86 Non-cardiovascular 
disease states such as asthma,69 7" hepatorenal ~yndrome,'~ 
and certain forms of ulcer also might be considered. 
Thus endothelin antagonists may provide new and 
potentially effective tools to interfere with vascular disease 
and its complications in different organs. Given this back- 
ground, the imminent availability of endothelin antagonists 
is an exciting prospect both for scientists and clinicians. 
As scientists and clinical investigators we certainly need 
endothelin antagonists to teach us more about the 
(patho)physiology of cardiovascular disease. In the not too 
Do we need endothelin antagonists? 209 1 
distant future, this will also allow us to answer the question 
whether as clinicians we truly need this new class of drugs 
to treat patients. 
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